<DOC>
	<DOCNO>NCT00619021</DOCNO>
	<brief_summary>RATIONALE : Bronchial artery infusion use catheter deliver antitumor substance directly lung . Drugs use chemotherapy , gemcitabine , work different way stop tumor cell divide stop grow die . Giving gemcitabine different way may kill tumor cell . PURPOSE : This phase I trial study side effect best dose gemcitabine give bronchial artery infusion see well work treat patient recurrent progressive non-small cell lung cancer .</brief_summary>
	<brief_title>Bronchial Artery Infusion Gemcitabine Treating Patients With Recurrent Progressive Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish maximum tolerate dose gemcitabine hydrochloride deliver via bronchial artery infusion patient recurrent progressive non-small cell lung cancer . Secondary - To evaluate local response patient treat therapy . - To characterize pharmacokinetics gemcitabine hydrochloride patient treat therapy . OUTLINE : This dose-escalation study gemcitabine hydrochloride deliver via bronchial artery infusion . Patients receive gemcitabine hydrochloride via bronchial artery infusion 30-60 minute day 1 via IV infusion 30 minute day 8 course 1 . Patients receive gemcitabine hydrochloride IV 30 minute day 1 8 subsequent course . Treatment repeat every 21 day absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 8 week 3 month 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Cytologically histologically confirm nonsmall cell lung cancer meeting follow criterion : No T2 lesion invade visceral pleura , cause atelectasis , proximal obstruct pneumonia No T3 lesion invade chest wall ( include parietal pleura , musculature , and/or rib ) , mediastinal pleura , diaphragm , pericardium No T4 lesion invade heart , great vessel , carina , esophagus Must disease incurable standard treatment , define minimum firstline therapy platinumcontaining regimen secondline therapy docetaxel , pemetrexed disodium , erlotinib hydrochloride Measurable nonmeasurable disease define Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Life expectancy ≥ 12 week Hemoglobin ≥ 9.0 g/dL Absolute neutrophil count ( ANC ) ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Serum creatinine ≤ 3.0 mg/dL Total bilirubin &lt; 1.5 time upper limit normal International normalized ratio ( INR ) ≤ 1.3 Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception Superior vena cava syndrome superior sulcus tumor Patients airway obstruct lesion , patient experience hemoptysis , dyspnea , chest pain , and/or copious sputum production may eligible careful consideration study physician Prior concurrent malignancy except inactive nonmelanoma skin cancer , carcinoma situ cervix , stage I carcinoma prostate normal PSA , cancer patient disease free 3 year Medical condition would make protocol unreasonably hazardous , opinion treat physician , include follow : Uncontrolled infection ( include HIV ) Poorly control diabetes mellitus Active cardiac disease ( i.e. , unstable angina , myocardial infarction within past 6 month , congestive heart failure ) Other serious medical illness would limit survival &lt; 3 month , psychiatric condition would prevent informed consent , unless legal guardian available Must consent participate laboratory study , `` Population Pharmacokinetics Pharmacogenetics Gemcitabine Adult Patients Solid Tumors '' course 1 More 6 month since prior gemcitabine hydrochloride More 2 week since prior chemotherapy More 4 week since prior radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
</DOC>